 |
 |  |
| The ISPOR mission is to translate pharmacoeconomics and outcomes research into practice. We encourage health care practitioners, health care purchasers, and health care decision-makers, as well as pharmacoeconomic and outcomes researchers to attend this meeting. | In this program, SPECIAL TRACKS are identified for the following:
|
 | Health care practitioner (physician, pharmacist, nurse, other health care professionals) |
 | Health care decision-maker & purchaser (health plans, insurance companies, government) |
 | Outcomes (quality-of-life) researchers |
 | Pharmacoeconomic (health economic) researchers |
| Choose your TRACK and follow the symbol in the program to help you select presentations that match your interest. |
| Wednesday, May 26, 1999 |
|
| 7:00AM - 8:00AM | CONTINENTAL BREAKFAST IN FOYER |
| 7:00AM - 8:00AM | CONTRIBUTED WORKSHOP SESSION 3 PRESENTER MEETING |
| 7:00AM - 8:00AM | EUROQOL GROUP BREAKFAST (open invitation to all ISPOR members) |
|
| 8:00 - 8:50AM | CONTRIBUTED WORKSHOPS - SESSION 3 |
|
| | WPE7
| SCHIZOPHRENIA: HELPING THE DECISION-MAKER TO UNDERSTAND THE IMPACTS OF ATYPICAL ANTIPSYCHOTICS
Mauskopf J1, David K1, Muroff M1, Grainger D2, Gibson PJ2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Eli Lilly & Company, Indianapolis, IN, USA |
| | WPE8
| DESIGNING NATURALISTIC OUTCOMES TRIALS THAT ARE APPLICABLE TO THE 'REAL WORLD' OF CLINICAL PRACTICE
Tunis SL, Melfi CA, Robinson R, Eli Lilly and Company, Indianapolis, IN, USA |
| | WPE10
| GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS: CURRENT USE AND EMERGING TRENDS
Munro V1, Geneste B2, Luce B3; 1MEDTAP International, London, UK; 2Rhöne Poulenc Rorer, Paris, France; 3MEDTAP International, Bethesda, MD, USA |
| | WTG2
| UPDATE ON THE SCRIPT PROJECT
Westrick E, Rhode Island Quality Partners, Providence, RI, USA |
| | WTG5
| EVALUATION OF FORMULARY DECISIONS: PROJECTED IMPACT OF A NEW DRUG ROLLOUT WITHIN THE MANAGED CARE ARENA
Wright A, Wolff J, Advance Paradigm, Inc., Hunt Valley, MD, USA |
| | WDM3
| APPLYING PRACTICAL APPLICATIONS OF PE AND OUTCOMES DATA IN THE COMMUNITY HEALTHCARE FACILITY
Santorello, JG, John T, Mather Memorial Hospital, Port Jefferson, NY, USA |
| | WMS2
| PITFALLS WHEN USING REGRESSION EQUATIONS TO ESTIMATE TREATMENT IMPACT IN ACTUAL PRACTICE
Caro JJ, Huybrechts KF, Klittich WS, Caro Research, Boston, MA, USA |
| | WMS5
| ASSESSING THE GENERALIZABILITY OF THE RESULTS OF MULTINATIONAL TRIALS FOR INDIVIDUAL COUNTRIES PARTICIPATING IN THE TRIAL
Glick H, Polsky D, University of Pennsylvania, Philadelphia, PA, USA |
| | WMD3
| NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING - PROCESS AND TECHNOLOGY
Jardina P, Irwin C, Physicians Data Corporation, Atlanta, GA, USA |
| | WMD4
| COMBINING MARKET DATA AND STATE-PREFERENCE DATA TO ESTIMATE DEMAND FOR A NEW PHARMACEUTICAL
Johnson FR, Desvousges WH, Knight TH, Bingham MF, Triangle Economic Research, Durham, NC, USA |
| | WMQ3
| EVALUATING HIV DISEASE HEALTH OUTCOMES IN DIFFERENT TREATMENT SETTINGS: HOW TO SELECT THE MOST APPROPRIATE HRQL INSTRUMENT
Berzon RA, Lenderking WR, Pashos CL, Abt Associates Clinical Trials, Cambridge, MA, USA |
| | WMM5 | USING EPIDEMIOLOGIC DATABASES TO EXTRAPOLATE LONG-TERM OUTCOMES FROM SURROGATE MARKER DATA
Huse DM, Russell MW, Medical Research International, Burlington, MA, USA |
|
| 9:00 - 9:50AM | CONTRIBUTED WORKSHOPS - SESSION 3R
(A repeat of SESSION 3 workshops) |
|
| 9:50 - 10:00AM | BREAK AND REFRESHMENTS IN FOYER |
10:00 - 2:00PM
 | ISPOR HEALTH POLICY SESSION
During this session, health policy issues impacting pharmacoeconomic and outcomes research will be debated - patient confidentiality, standardization of pharmacoeconomic methodology and quality of life guidances.
Moderators: Karl Matuszewski MS, PharmD, Director, Technology Assessment, University HealthSystem Consortium, Deerfield, IL, USA and ISPOR Legislative & Government Affairs - North America Chair and Louis Morris PhD, Senior Vice President, PRR Inc, Melville, NY, USA, and ISPOR Health Policy Development Chair |
10:00 - 10:40AM
| DATA PRIVACY, MEDICAL RECORD CONFIDENTIALITY, AND RESEARCH IN THE INTEREST OF THE PUBLIC HEALTH
Elizabeth Andrews PhD, Director, Worldwide Epidemiology, Glaxo-Wellcome, Research Triangle Park, NC, USA and ISPE 1998-99 President-elect
Government authorities are developing legislation on patient confidentiality, which will impact scientific information available to health care researchers. During this session, issues on patient confidentiality as it relates to scientific health care research will be presented.
The International Society for PharmacoEpidemiology (ISPE) "Data Privacy, Medical Record Confidentiality, and Research in the Interest of the Public Health" research policy initiative, endorsed by ISPOR, will be presented. Proposed US congressional legislation and its impact on pharmacoepidemiology and outcomes research will also be discussed. |
10:40 - 11:20AM
| MODELING FOR PUBLIC POLICY DECISIONS: USES, ROLES, AND VALIDITY
Milton C. Weinstein PhD, Professor Health Policy & Management, Harvard School of Public Health, Boston, MA, USA
To continue the ISPOR initiative to standardize pharmacoeconomic methodology, a discussion on modeling for public policy decisions as it relates to pharmacoeconomic modeling will be presented.
A survey of the uses of policy models in several areas of public- and private-sector decision making, with the objective of gaining insight into the appropriate roles of models in health care policy will be presented. Questions such as: to what degree models should be informed by directly observed, experimental data since, at some level, models are always used in the assessment of health benefits, risks, and costs and: Is it necessary, or even possible, to "validate" models after the fact? |
| 11:20 - 11:40AM | REFRESHMENT BREAK IN FOYER |
11:40 - 12:20PM
| EUROPEAN REGULATORY ISSUES ON QOL ASSESSMENT (ERIQA) PROJECT
Catherine Acquadro MD, Development Director, MAPI Research, Lyon, France
Health authorities are increasingly faced with health-related quality of life as a new criterion for evaluating drugs, biologicals, and devices. During this and the following presentation, issues on quality of life as well as health care outcomes assessment as it relates to health authority approval process will be presented.
The objectives of the ERIQA project are to: develop consensus on guidelines on the use of HRQoL data in clinical research; develop recommendations for regulatory agencies; and inform purchasers and funders on relevant HRQoL studies to health care decision process. ERIQA objectives and progress to date will be presented. |
12:20 - 1:00PM
| DEVELOPMENT OF QUALITY OF LIFE GUIDANCE FOR LABELING AND PROMOTION OF DRUGS, BIOLOGICALS, AND DEVICES BY THE FDA
Laurie Beth Burke RPh, MPH, Chief, Managed Care Outcomes, US Food and Drug Administration, Rockville, MD, USA
Progress in the development of Quality of Life Guidance for Labeling and Promotion of Drugs, Biologicals, and Devices by the FDA will be presented. |
| 1:00 - 2:00PM | ISPOR HEALTH POLICY DEVELOPMENT - AUDIENCE PARTICIPATION |
Annual International Meeting Main Page
|
|
|
